Takeda Pharmaceutical set to acquire TiGenix for €520m, enhancing gastroenterology and specialty care offerings
Japanese pharmaceutical giant Takeda Pharmaceutical has announced a proposal to acquire TiGenix, a Belgium-based cell therapy company, for €520 million. This acquisition is aimed at ... Read More
TiGenix reports success for AlloCSC-01 in Phase I/II heart failure study
TiGenix, a Belgium-based biopharmaceutical company, has announced promising results from its Phase I/II study assessing the safety and efficacy of AlloCSC-01, its innovative stem cell ... Read More